- Adrenomedullin (1-12), human
- Myelopeptide-2 (MP-2)
- Epidermal Growth Factor Receptor Peptide (985-996)
- GTP-Binding Protein Fragment, G alpha
- Laminin (925-933)
| Cytochrome P450 CYP1B1 (190-198) [Homo sapiens]Sequence: H2N-FLDPRPLTV-OH |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.32%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- MS (Mass Spectrometry)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] Dilution Calculator
calculate
Cytochrome P450 CYP1B1 (190-198) [Homo sapiens] Molarity Calculator
calculate
| Cas No. | N/A | SDF | Download SDF |
| Synonyms | H2N-Phe-Leu-Asp-Pro-Arg-Pro-Leu-Thr-Val-OH | ||
| Chemical Name | N/A | ||
| Canonical SMILES | NC(C(NC(CC(C)C)C(NC(CC(O)=O)C(N1C(C(NC(CCCNC(N)=N)C(N2CCCC2C(NC(CC(C)C)C(NC(C(C)O)C(NC(C(C)C)C(O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)CC3=CC=CC=C3 | ||
| Formula | C50H80N12O13 | M.Wt | 1057.24 |
| Solubility | ≥105.7mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
H2N-FLDPRPLTV-OH
Cytochrome P450 CYP1B1 is a dioxin-inducible form of the cytochrome P450 family of xenobiotic metabolizing enzymes1.
HLA-A2 restricted, CYP1B1 190–198 (CYP190) peptide specific T cell responses are induced in HLA-A2Kb transgenic mice by immunization with ZYC300, a PLG microparticle formulation that contains a plasmid DNA encoding the tumor associated antigen CYP1B12, 3.
Each successive co-application of EPT contributes to an escalating T cell response that can be observed 2 weeks after the last immunization, and that even a single EPT when given with the usually ineffective 30 µg dose of ZYC300 was able to induce a detectable CD8+ CYP190 specific T cell response4.
Figure1. Cytochrome P450 CYP1B1
Figure2. Formula of Cytochrome c fragment (93-108)
C50H80N12O13
Figure3.Location of Cytochrome P450 CYP1B1
The CYP1B1 gene is located on the short (p) arm of chromosome 2 at position 22.2.
Ref:
1. Murray,G.I., Taylor, M. C., et al 1997; Tumor-specific Expression of Cytochrome P450 CYP1B11. Cancer Research. 57:3026-3031.
2. Luby TM, Cole GA, Baker L, Kornher JS, Ramstedt U, Hedley ML. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor associated antigen cytochrome P450 1B1. Clinical Immunology 2004;112(1):45–53.
3. Maecker DH, Sherr RH, Vonderheide MS, von Bergwelt-Baildon MS, Hirano N, Anderson K, et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003;102(9):3287–94.
4. Barbon, C. M., Baker, L et al 2010 In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine; 28:7852-7864
